カテゴリー： GlobalData, 企業調査

RXi Pharmaceuticals Corp (RXII)：製薬・医療：M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書（DATA904C8249）
◆英語タイトル：RXi Pharmaceuticals Corp (RXII) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8249
◆発行会社（リサーチ会社）：GlobalData
◆発行日：2018年10月
◆ページ数：75
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥34,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥69,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥103,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

 【レポートの概要】

Summary
RXi Pharmaceuticals Corp (RXi) is a biotechnology company that discovers, develops and commercializes immuno-oncology therapeutics to treat cancer. The company’s technology sd-rxRNA includes RXI-109 and IncRNA. Its lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways in fibrosis including scar formation in the skin and eye. RXi also provides clinical trial services. It offers products for the treatment of anti scarring, macular degeneration, retinoblastoma, and liver diseases. The company partners with academia, biotech, and large multi-national organizations for the development of new therapeutics. RXi is headquartered in Marlborough, Massachusetts, the US.

RXi Pharmaceuticals Corp (RXII) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
RXi Pharma Acquires RNAi-Related Assets from Opko Health 13
Partnerships 15
RXi Pharma and Karolinska Institutet Enter into Research Partnership 15
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 16
MediGene Enters into Research Agreement with RXi Pharma 17
RXi Pharma Enters into Research Agreement with Center for Cancer ImmuneTherapy 18
RXi Pharma and Gustave Roussy Enter into Research Agreement 19
PCI Biotech Extends Research Agreement with RXi Pharma 20
RXi Pharma And Ethicor Enter Into Distribution Agreement For RXI-109 21
Licensing Agreements 22
Thera Neuropharma Enters into Licensing Agreement with RXi Pharma 22
RXi Pharma Enters into Licensing Agreement with MirImmune for Self-Delivering RNAi Technology 23
RXi Pharma Enters into Licensing Agreement with Hapten Pharma for Samcyprone 24
Equity Offering 25
RXi Pharma Raises USD15 Million in Public Offering of Units 25
RXi Pharma Plans to Raise up to USD2.9 Million in Public Offering of Shares 26
RXi Pharma Plans to Raise USD100 Million in Public Offering of Securities 27
RXi Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 28
RXi Pharma to Raise up to USD15 Million in Private Placement of Shares 29
RXi Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 31
RXi Pharma Completes Public Offering of Units for USD11.5 Million 32
RXi Pharma Raises USD10.4 Million in Public Offering of Units 34
RXi Pharmaceuticals Raises USD2 Million in Issue of Shares 36
RXi Pharma Completes First Tranche Of Private Placement Of Shares For US$2 Million 37
RXi Pharma Completes Private Placement Of Shares For US$16 Million 38
Acquisition 39
RXi Pharma Acquires MirImmune 39
OPKO Health Acquires 5.11% Stake in RXi Pharma 40
RXi Pharmaceuticals Corp – Key Competitors 41
RXi Pharmaceuticals Corp – Key Employees 42
RXi Pharmaceuticals Corp – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Strategy And Business Planning 44
Jan 16, 2018: RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth 44
Financial Announcements 46
Aug 14, 2018: RXi Pharmaceuticals announces second quarter 2018 financial results 46
May 10, 2018: RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 48
Mar 26, 2018: RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights 50
Nov 08, 2017: RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 53
Aug 10, 2017: RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 56
May 11, 2017: RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights 59
Mar 30, 2017: RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights 62
Corporate Communications 65
Sep 15, 2017: RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer 65
Jun 07, 2017: RXi Pharmaceuticals Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors 66
Apr 18, 2017: RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes 67
Feb 07, 2017: RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board 68
Jan 09, 2017: Rxi Pharmaceuticals Appoints New Chief Business Officer 69
Product News 70
Nov 29, 2017: RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program 70
04/16/2018: RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma 71
Clinical Trials 72
Aug 08, 2017: RXi Pharmaceuticals Selects RXI-762 for Preclinical Development 72
Aug 08, 2017: RXi Pharmaceuticals Selects RXI-804 for Preclinical Development 73
Other Significant Developments 74
Nov 07, 2017: RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RXi Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 9
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RXi Pharma Acquires RNAi-Related Assets from Opko Health 13
RXi Pharma and Karolinska Institutet Enter into Research Partnership 15
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 16
MediGene Enters into Research Agreement with RXi Pharma 17
RXi Pharma Enters into Research Agreement with Center for Cancer ImmuneTherapy 18
RXi Pharma and Gustave Roussy Enter into Research Agreement 19
PCI Biotech Extends Research Agreement with RXi Pharma 20
RXi Pharma And Ethicor Enter Into Distribution Agreement For RXI-109 21
Thera Neuropharma Enters into Licensing Agreement with RXi Pharma 22
RXi Pharma Enters into Licensing Agreement with MirImmune for Self-Delivering RNAi Technology 23
RXi Pharma Enters into Licensing Agreement with Hapten Pharma for Samcyprone 24
RXi Pharma Raises USD15 Million in Public Offering of Units 25
RXi Pharma Plans to Raise up to USD2.9 Million in Public Offering of Shares 26
RXi Pharma Plans to Raise USD100 Million in Public Offering of Securities 27
RXi Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 28
RXi Pharma to Raise up to USD15 Million in Private Placement of Shares 29
RXi Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 31
RXi Pharma Completes Public Offering of Units for USD11.5 Million 32
RXi Pharma Raises USD10.4 Million in Public Offering of Units 34
RXi Pharmaceuticals Raises USD2 Million in Issue of Shares 36
RXi Pharma Completes First Tranche Of Private Placement Of Shares For US$2 Million 37
RXi Pharma Completes Private Placement Of Shares For US$16 Million 38
RXi Pharma Acquires MirImmune 39
OPKO Health Acquires 5.11% Stake in RXi Pharma 40
RXi Pharmaceuticals Corp, Key Competitors 41
RXi Pharmaceuticals Corp, Key Employees 42
RXi Pharmaceuticals Corp, Subsidiaries 43

List of Figures
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RXi Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ RXi Pharmaceuticals Corp (RXII)：製薬・医療：M&Aディール及び事業提携情報(RXi Pharmaceuticals Corp (RXII) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • Central Alabama Electric Cooperative Inc：企業の戦略的SWOT分析 Central Alabama Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A...
  • DeepOcean Group Holding BV：企業の戦略的SWOT分析 DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed...
  • Kajima Corp (1812)：企業の財務・戦略的SWOT分析 Kajima Corp (1812) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s...
  • Shanghai Pharmaceutical Co Ltd (601607)：医療機器：M&Aディール及び事業提携情報 Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic anti-infection, and antineoplastic drug and immunomodulator. It also offers pharmaceuticals for diseases and disorders of cardiovascular system, digestive and metabolism, neurological system, musculoskeletal system, and respiratory system. The company also provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. Shanghai Pharma also provides traditional Chinese medicines....
  • Tauron Polska Energia SA：企業の発電所・SWOT分析2018 Tauron Polska Energia SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized and detailed information about the power plants (assets). - Operational Metrics (capacity, generation, revenue, sales, number of consumers). - Business description - A detailed description of the company’s operations and business divisions. - Corporate strategy - GlobalData’s summarization of the company’s business strategy....
  • Kurabo Industries Ltd (3106)：企業の財務・戦略的SWOT分析 Kurabo Industries Ltd (3106) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy –...
  • Covalon Technologies Ltd (COV)：製品パイプライン分析 Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen matrix dressing, collagen matrix dressing with silver, wound contact layer, non-adherent foam dressing and superabsorbent dressing, among others. Its infection prevention products and perioperative care product includes self-adherent silicone dressing with absorbent pad, antimicrobial clear silicone adhesive dressing with chlorhexidine and silver and silicone foley catheter, among others. The company also develops and commercializes proprietary technologies in the areas of advanced wound...
  • GlaxoSmithKline Plc (GSK)-医療機器分野：企業M&A・提携分析 Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex,...
    • ◆H&Iグローバルリサーチのお客様（例）◆